NewsBenzingaOppenheimer mantiene su recomendación de sobreponderar sobre BioMarin Pharmaceutical y reduce el precio objetivo a 94 dólares. Oppenheimer mantiene su recomendación de sobreponderar sobre BioMarin Pharmaceutical y reduce el precio objetivo a 94 dólares. Benzinga 2026.11.03 17:11 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Neutral on Check Point Software Tech, Lowers Price Target to $155 'Amazon, Tesla and SpaceX join OKX–ICE tokenized stock objections as deadline looms' - CoinDesk JP Morgan Maintains Overweight on Apple, Lowers Price Target to $355 'HSBC, JPMorgan Offer to Help Development Banks Get Capital Relief' - Bloomberg Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027 JP Morgan Maintains Overweight on Afya, Lowers Price Target to $17.5
